| Structure |
Chemical Name |
CAS |
MF |
 |
Voreloxin |
175414-77-4 |
C18H19N5O4S |
 |
Z-PHE-DL-ALA-FLUOROMETHYLKETONE |
197855-65-5 |
C21H23FN2O4 |
 |
FLI-06 |
313967-18-9 |
C25H30N2O5 |
 |
MMP-2/MMP-9 INHIBITOR IV |
292605-14-2 |
C15H14O3S2 |
 |
Teneligliptin Hydrobromide |
906093-29-6 |
C22H31BrN6OS |
 |
AT-101 |
866541-93-7 |
C32H34O10 |
 |
RG-7388 |
1229705-06-9 |
C31H29Cl2F2N3O4 |
 |
GSK2656157 |
1337532-29-2 |
C23H21FN6O |
 |
AZD 9668 |
848141-11-7 |
C25H22F3N5O4S |
 |
NSC319726 |
71555-25-4 |
C11H14N4S |
![4-[[4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone](/CAS2/GIF/890090-75-2.gif) |
4-[[4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone |
890090-75-2 |
C30H30Cl2N4O4 |
 |
Nutlin-3b |
675576-97-3 |
C30H30Cl2N4O4 |
 |
BAM7 |
331244-89-4 |
C21H19N5O2S |
 |
4-(4-Methyl-1-piperazinyl)-7-nitrobenzofurazane 3-oxide |
58131-57-0 |
C11H13N5O4 |
 |
GDC-0152 |
873652-48-3 |
C25H34N6O3S |
 |
Refametinib |
923032-37-5 |
C19H20F3IN2O5S |
 |
Losmapimod (GW856553X) |
585543-15-3 |
C22H26FN3O2 |
 |
Encorafenib (LGX818) |
1269440-17-6 |
C22H27ClFN7O4S |
 |
CGS 21680A |
124431-80-7 |
C23H30ClN7O6 |
 |
LDN-193189 HCl |
1062368-62-0 |
C25H23ClN6 |
 |
Fasiglifam (TAK-875) Hemihydrate |
1374598-80-7 |
C58H66O15S2 |
 |
GNE 7915 |
1351761-44-8 |
C19H21F4N5O3 |
 |
P 22077 |
1247819-59-5 |
C12H7F2NO3S2 |
 |
N-(2-METHYL-6-BENZOOXAZOLYL)-N''-1,5-NAPHTHYRIDIN-4-YL UREA |
792173-99-0 |
C17H13N5O2 |
![6,8-Difluoro-4-pyridin-3-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline](/CAS/GIF/1139889-93-2.gif) |
6,8-Difluoro-4-pyridin-3-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline |
1139889-93-2 |
C17H14F2N2 |
 |
IKK Inhibitor III, BMS-345541 |
445430-58-0 |
C14H17N5 |
 |
CEP-32496 (free base) |
1188910-76-0 |
C24H22F3N5O5 |
 |
K 02288 |
1431985-92-0 |
C20H20N2O4 |
 |
ML-323 |
1572414-83-5 |
C23H24N6 |
 |
LDN212854 |
1432597-26-6 |
C25H22N6 |
 |
GW 842166X |
666260-75-9 |
C18H17Cl2F3N4O2 |
![4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline](/CAS/GIF/1206711-16-1.gif) |
4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline |
1206711-16-1 |
C24H20N4O |
![2-[[2-Ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one](/CAS/GIF/1234480-50-2.gif) |
2-[[2-Ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one |
1234480-50-2 |
C26H30N6O3 |
 |
(R)-2-((R)-6,7-diMethoxy-1-(4-(trifluoroMethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-Methyl-2-phenylacetaMide |
913358-93-7 |
C29H31F3N2O3 |
 |
MK-2048 |
869901-69-9 |
C21H21ClFN5O4 |
 |
AHAS inhibitor |
219793-45-0 |
C19H12ClNO6S |
 |
CEP 33779 |
1257704-57-6 |
C24H26N6O2S |
 |
Dolutegravir sodium |
1051375-19-9 |
C20H20F2N3NaO5 |
 |
pf-5274857 |
1373615-35-0 |
C20H25ClN4O3S |
 |
ML 133 Hydrochloride |
1222781-70-5 |
C19H20ClNO |
![5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine](/CAS/GIF/865362-74-9.gif) |
5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine |
865362-74-9 |
C18H13N7 |
 |
Ki16198 |
355025-13-7 |
C24H25ClN2O5S |
 |
LGK-974 |
1243244-14-5 |
C23H20N6O |
![7-Methyl-5-[(3-piperazin-1-ylMethyl)-1,2,4-oxadiazol-5-yl-]-2-[4-(trifluoroMethoxy)benzyl]-2,3-dihydro-1H-isoindol-1-one Methanesulphonate](/CAS/20150408/GIF/802904-66-1.gif) |
7-Methyl-5-[(3-piperazin-1-ylMethyl)-1,2,4-oxadiazol-5-yl-]-2-[4-(trifluoroMethoxy)benzyl]-2,3-dihydro-1H-isoindol-1-one Methanesulphonate |
802904-66-1 |
C19H17ClN2O3S |
 |
(Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3- |
1421919-75-6 |
C16H10F8N4O |
 |
SD-208 |
627536-09-8 |
C17H10ClFN6 |
 |
JNK-IN-8 |
1410880-22-6 |
C29H29N7O2 |
 |
S-Ruxolitinib (INCB018424) |
941685-37-6 |
C17H18N6 |
![5-[6-(4-Methoxyphenyl)pyrazolo[1,5-a]](/CAS/20150408/GIF/1062368-49-3.gif) |
5-[6-(4-Methoxyphenyl)pyrazolo[1,5-a] |
1062368-49-3 |
C22H16N4O |
 |
WS6 |
1421227-53-3 |
C29H31F3N6O3 |
 |
PF-543 |
1415562-82-1 |
C27H31NO4S |
 |
IWP L6 |
1427782-89-5 |
C25H20N4O2S2 |
 |
IKK 16 |
873225-46-8 |
C28H29N5OS |
 |
b-AP15 |
1009817-63-3 |
C22H17N3O6 |
 |
DBeQ |
177355-84-9 |
C22H20N4 |
![L-Phenylalanine, 4-[bis(2-chloroethyl)oxidoaMino]-, (Hydrochloride) (1:2)](/CAS/GIF/685898-44-6.gif) |
L-Phenylalanine, 4-[bis(2-chloroethyl)oxidoaMino]-, (Hydrochloride) (1:2) |
685898-44-6 |
C13H19Cl3N2O3 |
 |
RGFP 109 |
1215493-56-3 |
C20H25N3O2 |
 |
Cabotegravir (GSK744, GSK1265744) |
1051375-10-0 |
C19H17F2N3O5 |
 |
Verdinexor (KPT-335) |
1392136-43-4 |
C18H12F6N6O |
 |
VER-49009 |
940289-57-6 |
C19H18ClN3O4 |
 |
Nodinitib-1 |
799264-47-4 |
C14H13N3O2S |
 |
OG-L002 |
1357302-64-7 |
C15H15NO |
 |
Selinexor |
1393477-72-9 |
C17H11F6N7O |
 |
WS3 |
1421227-52-2 |
C28H30F3N7O3 |
 |
Raf265 derivative |
1942849-27-5 |
C23H14F6N6O |
 |
LMK-235 |
1418033-25-6 |
C15H22N2O4 |
 |
Cathepsin Inhibitor 1 |
225120-65-0 |
C20H24ClN5O2 |
 |
RGFP966 |
1396841-57-8 |
C21H19FN4O |
 |
ReModelin hydrobroMide |
1622921-15-6 |
C15H15BrN4S |
 |
WIKI4 |
838818-26-1 |
C29H23N5O3S |
 |
PD 151746 |
179461-52-0 |
C11H8FNO2S |
 |
BI-97C1 |
1228108-65-3 |
C42H40N2O8 |
 |
Tubastatin-A |
1252003-15-8 |
C20H21N3O2 |
 |
PI-1840 |
1401223-22-0 |
C22H26N4O3 |
 |
SCR7 |
1533426-72-0 |
C18H14N4OS |
 |
CPI-203 |
1446144-04-2 |
C19H18ClN5OS |
 |
HO-3867 |
1172133-28-6 |
C28H30F2N2O2 |
 |
GNE-0877 |
1374828-69-9 |
C14H16F3N7 |
 |
LFM-A13 |
244240-24-2 |
C11H8Br2N2O2 |
 |
PYR 41 |
418805-02-4 |
C17H13N3O7 |
 |
ZM 39923 HCl |
1021868-92-7 |
C23H26ClNO |
 |
NSC697923 |
343351-67-7 |
C11H9NO5S |
 |
GSK1324726A (I-BET726) |
1300031-52-0 |
C25H23ClN2O3 |
 |
BV6 |
1001600-56-1 |
C70H96N10O8 |
 |
BAF-312(SiponiMod) |
1230487-00-9 |
C29H35F3N2O3 |
 |
PFI3 |
1819363-80-8 |
C19H19N3O2 |
 |
MG149 |
1243583-85-8 |
C22H28O3 |
 |
ARQ 621 |
1095253-39-6 |
C28H24Cl2FN5O2 |
 |
CH5138303 |
959763-06-5 |
C19H18ClN5O2S |
 |
ISRIB (trans-isoMer) |
1597403-47-8 |
C22H24Cl2N2O4 |
 |
GNE-9605 |
1536200-31-3 |
C17H20ClF4N7O |
 |
CAY10683 (SantacruzaMate A) |
1477949-42-0 |
C15H22N2O3 |
 |
GZD824 |
1421783-64-3 |
C31H35F3N6O7S2 |
 |
YH239-EE |
1364488-67-4 |
C25H27Cl2N3O4 |
 |
Defactinib |
1073154-85-4 |
C20H21F3N8O3S |
 |
Triapine |
200933-27-3 |
C7H9N5S |
 |
LRRK2-kinase inhibitor |
1285515-21-0 |
C24H18FN3O2 |
 |
LDN-214117 |
1627503-67-6 |
C25H29N3O3 |
 |
SH-4-54 |
1456632-40-8 |
C29H27F5N2O5S |
 |
GSK-LSD1 |
1431368-48-7 |
C14H20N2 |